A detailed history of Price T Rowe Associates Inc transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 236,100 shares of SGMO stock, worth $481,644. This represents 0.0% of its overall portfolio holdings.

Number of Shares
236,100
Previous 278,704 15.29%
Holding current value
$481,644
Previous $187,000 55.61%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.36 - $0.65 $15,337 - $27,692
-42,604 Reduced 15.29%
236,100 $83,000
Q1 2024

May 15, 2024

BUY
$0.42 - $1.38 $4,356 - $14,314
10,373 Added 3.87%
278,704 $187,000
Q4 2023

Feb 14, 2024

BUY
$0.3 - $0.63 $965 - $2,027
3,218 Added 1.21%
268,331 $146,000
Q3 2023

Nov 14, 2023

BUY
$0.58 - $1.47 $20,468 - $51,876
35,290 Added 15.36%
265,113 $160,000
Q2 2023

Aug 14, 2023

BUY
$1.11 - $1.74 $5,142 - $8,061
4,633 Added 2.06%
229,823 $299,000
Q1 2023

May 15, 2023

BUY
$1.66 - $3.67 $107,964 - $238,693
65,039 Added 40.61%
225,190 $397,000
Q4 2022

Feb 14, 2023

BUY
$2.77 - $5.07 $13,891 - $25,426
5,015 Added 3.23%
160,151 $503,000
Q3 2022

Nov 14, 2022

BUY
$4.27 - $6.39 $37,687 - $56,398
8,826 Added 6.03%
155,136 $761,000
Q2 2022

Aug 15, 2022

BUY
$3.28 - $6.21 $18,696 - $35,397
5,700 Added 4.05%
146,310 $606,000
Q1 2022

May 16, 2022

BUY
$5.23 - $7.82 $12,782 - $19,112
2,444 Added 1.77%
140,610 $817,000
Q4 2021

Feb 14, 2022

BUY
$7.29 - $10.97 $360,512 - $542,499
49,453 Added 55.74%
138,166 $1.04 Million
Q3 2021

Nov 15, 2021

BUY
$9.01 - $12.01 $61,997 - $82,640
6,881 Added 8.41%
88,713 $799,000
Q2 2021

Aug 16, 2021

SELL
$10.17 - $12.64 $76,773 - $95,419
-7,549 Reduced 8.45%
81,832 $980,000
Q1 2021

May 17, 2021

SELL
$10.88 - $17.05 $559,112 - $876,182
-51,389 Reduced 36.51%
89,381 $1.12 Million
Q4 2020

Feb 16, 2021

BUY
$9.23 - $18.18 $1.3 Million - $2.56 Million
140,770 New
140,770 $2.2 Million

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $319M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.